Understanding side effects of therapy for myasthenia gravis and their impact on daily life

被引:37
作者
Bacci, Elizabeth Dansie [1 ]
Coyne, Karin S. [2 ]
Poon, Jiat-Ling [3 ]
Harris, Linda [4 ]
Boscoe, Audra N. [5 ]
机构
[1] Evidera, Patient Ctr Res, 1417 Fourth Ave,Suite 510, Seattle, WA 98101 USA
[2] Evidera, Patient Ctr Res, Bethesda, MD USA
[3] Eli Lilly, Patient Focused Outcomes Ctr Expertise, Indianapolis, IN USA
[4] Alexion Pharmaceut Inc, Global Hlth Outcomes Res, New Haven, CT USA
[5] Agios Pharmaceut, Hlth Econ & Outcomes Res, Cambridge, MA USA
关键词
Myasthenia gravis; MG; Adherence to treatment; Side effects; Health-related quality of life; QUALITY-OF-LIFE; TRIAL;
D O I
10.1186/s12883-019-1573-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Myasthenia gravis is a chronic, autoimmune, neuromuscular junction disorder characterized by skeletal muscle weakness. Current therapies for myasthenia gravis are associated with significant side effects. The objective of this study was to characterize the side effects, and associated health-related quality of life and treatment impacts, of traditional myasthenia gravis treatments. Methods This study had two phases; a Phase 1 interview and a 2-part web-based survey in Phase 2 that included brainstorming (Step 1) and rating (Step 2) exercises using group concept mapping. In Phase 1, all 14 participants reported experiencing side effects from myasthenia gravis treatments which had significant impacts on daily life. In Phase 2, 246 participants contributed to Step 1; 158 returned for Step 2. Results The brainstorming exercise produced 874 statements about side effects and their impact, which were reduced to 35 side effects and 23 impact-on-daily life statements. When rating these statements on severity, frequency, and tolerability, blood clots, infections/decreased immunity, weight gain, and diarrhea were the least tolerable and most severely rated. The most frequent and severe impacts were sleep interference and reduced physical and social activities. Conclusions Based on these findings, there appears to be a need for better and more tolerable treatments for myasthenia gravis patients.
引用
收藏
页数:13
相关论文
共 18 条
[1]   An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts [J].
Boldingh, M. I. ;
Dekker, L. ;
Maniaol, A. H. ;
Brunborg, C. ;
Lipka, A. F. ;
Niks, E. H. ;
Verschuuren, J. J. G. M. ;
Tallaksen, C. M. E. .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2015, 13
[2]   Less is more, or almost as much: A 15-item quality-of-life instrument for myasthenia gravis [J].
Burns, Ted M. ;
Conaway, Mark R. ;
Cutter, Gary R. ;
Sanders, Donald B. .
MUSCLE & NERVE, 2008, 38 (02) :957-963
[3]   THE MG-QOL15 FOR FOLLOWING THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH MYASTHENIA GRAVIS [J].
Burns, Ted M. ;
Grouse, C. K. ;
Wolfe, Gil I. ;
Conaway, Mark R. ;
Sanders, Donald B. .
MUSCLE & NERVE, 2011, 43 (01) :14-18
[4]   CONSTRUCT AND CONCURRENT VALIDATION OF THE MG-QOL15 IN THE PRACTICE SETTING [J].
Burns, Ted M. ;
Grouse, C. K. ;
Conaway, Mark R. ;
Sanders, Donald B. .
MUSCLE & NERVE, 2010, 41 (02) :219-226
[5]   Unsatisfactory outcomes in myasthenia gravis: influence by care providers [J].
Dunand, Murielle ;
Botez, Stephan A. ;
Borruat, Francois-Xavier ;
Roux-Lombard, Pascale ;
Spertini, Francois ;
Kuntzer, Thierry .
JOURNAL OF NEUROLOGY, 2010, 257 (03) :338-343
[6]   Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis [J].
Gajdos, P ;
Chevret, S ;
Clair, B ;
Tranchant, C ;
Chastang, C .
ANNALS OF NEUROLOGY, 1997, 41 (06) :789-796
[7]   Conceptualizing and prioritizing clinical trial outcomes from the perspectives of people with Parkinson's disease versus health care professionals: a concept mapping study [J].
Hammarlund, Catharina Sjodahl ;
Nilsson, Maria H. ;
Idvall, Markus ;
Rosas, Scott R. ;
Hagell, Peter .
QUALITY OF LIFE RESEARCH, 2014, 23 (06) :1687-1700
[8]  
Howard JF Jr, 2015, CLIN OVERVIEW MG
[9]   Myasthenia gravis [J].
Juel, Vern C. ;
Massey, Janice M. .
ORPHANET JOURNAL OF RARE DISEASES, 2007, 2 (1)
[10]  
Krousel-Wood M, 2009, AM J MANAG CARE, V15, P59